Search Results for: *

Pediatric Neurodevelopmental Disorders

With comprehensive care from start to finish, GeneDx offers more than a test result. Experience the GeneDx difference and help your patients find answers. COMMON QUESTIONS *Fictionalized case study for illustrative purposes only References

2024 ACMG Annual Clinical Genetics Meeting

Equitable access to Exomes and Genomes. Ordered by whom? This debate-style session will provide a forum for the Medical Genetics and Genomics community to examine evidence and opinions that are both for and against the ordering of exome and genome sequencing by non-genetics healthcare professionals. The session will feature a moderator and a panel of 2024 ACMG Annual Clinical Genetics Meeting

In-Network Insurance Contracts

We are proud to be in-network with many commercial and government payors. In-network status may not apply for all health plan types, in all geographies, or for all health plan network products, so we encourage ordering providers and patients to check the health plan for provider network status ahead of services being rendered. Additionally, network In-Network Insurance Contracts

Targeted Variant Testing

When genetic testing identifies variant(s) in a patient, targeted variant testing may be indicated for family members. Targeted variant testing is less costly than diagnostic analysis of the whole gene or panel of genes. Additionally, in most cases targeted variant testing for pathogenic or likely pathogenic variant(s) will provide a straightforward “negative” or “positive” result. Targeted Variant Testing

Whole Genome Sequencing

Benefits of Whole Genome Sequencing Whole genome sequencing (WGS), also called genome testing, examines a person’s entire genome, including the protein-coding regions (called exons) and the non-coding regions (called introns). As a result, it is the most comprehensive genetic testing option available and enables the greatest chance of uncovering a genetic diagnosis. The Power of Whole Genome Sequencing

Whole Exome Sequencing

Benefits of Whole Exome Sequencing Comprehensive evaluations. Clearer insights.   Whole exome sequencing (WES), also called exome testing, targets the protein-coding regions of approximately 20,000 genes, which can provide more comprehensive insights than other testing modalities such as chromosomal microarray (CMA) and panel testing.  The Power of the Trio When both biological parents* include samples along Whole Exome Sequencing

Test Menu Changes

Important Information Regarding GeneDx Test Menu Changes  The information below outlines details regarding GeneDx tests that will be discontinued effective March 04, 2024. We will continue to offer a robust genetic testing menu, and for a subset of the tests being discontinued, potential alternative tests have been identified to support you and your patients. Below Test Menu Changes

Hereditary Cancer Testing

Go Deeper, See More Extensive and flexible hereditary cancer testing options to aid in personalized medical management. A legacy of expertise  Our expertise in hereditary cancer began over a decade ago, founded by cancer-focused genetic counselors and molecular geneticists who wanted to lead genetic testing in clinical oncology. Today, we’re known for our expertise utilizing Hereditary Cancer Testing

Other Cultured Cells Requirements

Other cultured adherent cells* (not amnio/CVS), collection, and shipping instructions Volume Send 2 T25 flasks near confluence, sterile. Please state the tissue of origin. Labeling Label with the patient name plus a second identifier such as date of birth, specimen ID or medical record number. Name and 2nd identifier on the specimen label must match Other Cultured Cells Requirements

DNA Requirements

Acceptable sources DNA extracted from whole blood, buccal swab, saliva, fresh and frozen tissue, bone marrow, dried blood spots. *We DO NOT accept DNA from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue. * **DNA MUST BE EXTRACTED IN A CLIA-certified Laboratory OR a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.** Amount 5 μg DNA Requirements